Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 4/20 | 0.35 |
| ▸ | BTK | Q06187 | 2/20 | 0.34 |
| ▸ | AOC1 | P19801 | 4/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29399289 | 1.00 | PDK2 (0.39) | PDK2GPR119AAK1F2BTK | |
| SCHEMBL25810945 | 0.90 | BTK (0.35) | PDK2GPR119BTKAOC1AOC3 | |
| SCHEMBL22366747 | 0.84 | AOC1 (0.37) | BTKAOC1AOC3KDM4EALDH1A1 | |
| SCHEMBL30743465 | 0.83 | SSTR4 (0.42) | PDK2GPR119AAK1F2BTK | |
| SCHEMBL30743498 | 0.82 | PDK2 (0.40) | PDK2GPR119AAK1F2BTK | |
| SCHEMBL29398613 | 0.81 | PDK2 (0.41) | PDK2GPR119 | |
| SCHEMBL17962481 | 0.78 | CHRNB2 (0.50) | AOC1AOC3 | |
| SCHEMBL29784871 | 0.78 | CHRNB2 (0.50) | AOC1AOC3 | |
| SCHEMBL29784870 | 0.78 | CHRNB2 (0.50) | AOC1AOC3 | |
| SCHEMBL22551824 | 0.78 | PDK2 (0.42) | PDK2AAK1F2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339157-B1 | 4H-pyrrolo[3,2-c]pyridin-4-one derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2022-05-24 | — | — | US | disclosed |
| WO-2022033416-A1 | FUSED RING COMPOUND AS EGFR INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海和誉生物医药科技有限公司 | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339157-B1 | 4H-pyrrolo[3,2-c]pyridin-4-one derivatives | CYP4B1, CYP2C19, CYP3A4 | PDK2 78/4885GPR119 1948/4885AAK1 4252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.